Drug Discovery Stories
From Bench to Bedside
- 1st Edition - October 1, 2024
- Editors: Bin Yu, Peng Zhan
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 3 9 3 2 - 8
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 3 9 3 3 - 5
Drug Discovery Stories: From Bench to Bedside presents a collection of cases on the development of highly successful pharmaceuticals. It delves into the realm of drug discovery… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteDrug Discovery Stories: From Bench to Bedside presents a collection of cases on the development of highly successful pharmaceuticals. It delves into the realm of drug discovery, exploring the structural biology and biological functions of the sought-after targets. The book covers the identification of promising compounds, their transformation from hits to leads through meticulous optimization, and the elucidation of how key compounds interact with the target (in essence, providing invaluable insights for drug design). Additionally, it covers essential information such as the pivotal biological and PK data of lead compounds, any noteworthy clinical results, and a comprehensive overview of other candidate compounds.
The field of drug discovery and development has experienced rapid evolution, with numerous new drugs receiving approval each year. While several books have been published on this subject, there is a pressing need for a new book series that accurately reflects the current advancements in drug discovery. This book aims to not only cater to the drug discovery community but also engage other communities involved in chemical biology, synthetic chemistry, and pharmacology.
- Analyzes the drug discovery stories of different blockbuster drugs
- Includes the newly approved drugs
- Covers key aspects related to the drug development of the drugs
Graduate students and researchers working with Drug Discovery, Medicinal Chemistry, Chemical Biology and Synthetic Chemistry
Section 1: Drug discovery techniques and Strategies
1. Artificial Intelligence in Early Stages of Structure-Based Drug Discovery
2. Target-based vs Phenotypic drug discovery: Opportunities and challenges with evidence-based application
3. Hit Discovery from DNA-Encoded Chemical Libraries
4. Discovery of Lead Compounds from Pseudo-Natural Macrocycles Enabled by Modular Biomimetic Strategy
5. Macrocyclization strategy in kinase drug discovery
6. Cobalt catalyzed C-H functionalization for the synthesis of chiral heterocyclic molecules
7. Advancing Proteolysis Targeting Chimeras towards Clinical Drug Developments
8. A future battle, small molecule drugs for cancer stem cell targeted therapy
9. Stem cell therapies for combating emerging and re-emerging viral infections
10. Targeting Autophagy with Pharmacological Small-Molecules to Treat Human Diseases
11. Interferons in human papillomavirus infection: antiviral effectors or immunopathogenic role?
12. Selenium and small molecules: a symbiotic partnership
13. Novel Combinations of CD33-Targeted Immunotherapies
14. Novel payloads of antibody–drug conjugates
15. Antibody-Drug Conjugates (ADCs): A New Generation of Cancer Vaccines
16. mRNA Vaccines: The Next Frontier in Disease Prevention
17. Unravelling the drying techniques of protein biopharmaceuticals
Section 2: Drug discovery case studies
18. Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatmet of multidrig-resistant HIV infections
19. Nirmatrelvir, SIM0417, and RAY1216: Potent and Selective SARS-CoV-2 Main Protease Inhibitors for the Potential Treatment of COVID-19
20. ARV-110: An Androgen Receptor Degrader in the Treatment of Metastatic Castration-Resistant Prostate Cancer
21. Darolutamide: An Androgen Receptor Antagonist for the Treatment of Prostate Cancer
22. Palbociclib, Ribociclib, and Abemaciclib: Potent and Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer
23. Zanubrutinib: A breakthrough in cancer therapy targeting BTK, originating from China and benefiting the global community
24. Discovery of FT-2102 (olutasidenib), an inhibitor of mutant isocitrate dehydrogenase 1, for treatment of relapsed or refractory acute myeloid leukemia
25. Ziftomenib (KO-539): A Potent and Selective Menin Inhibitor for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
26. Pulrodemstat (CC-90011): A Potent, Selective, and Reversible LSD1 Inhibitor
27. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
28. Verquvo, a First-in-Class Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Heart Failure
29. Tafamidis: a Transthyretin Stabilizer for Rare Cardiac Amyloidosis
30. Oliceridine (TRV-130): A Biased Agonist of the μ Opioid Receptor as a Novel Analgesic
31. Sotyktu (Deucravacitinib): The First TYK2 Inhibitor Approved for the Treatment of Psoriasis
32. Bexagliflozin: A SGLT-2 Inhibitor as Antidiabetic Drug Derived From Phlorizin
33. Antidiabetic Drugs Targeted PPARγ: From Full Agonists to Selective Modulators
34. Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis
35. Lecanemab (Leqembi): An Amyloid Beta Monoclonal Antibody Approved for the Treatment of Alzheimer's Disease
1. Artificial Intelligence in Early Stages of Structure-Based Drug Discovery
2. Target-based vs Phenotypic drug discovery: Opportunities and challenges with evidence-based application
3. Hit Discovery from DNA-Encoded Chemical Libraries
4. Discovery of Lead Compounds from Pseudo-Natural Macrocycles Enabled by Modular Biomimetic Strategy
5. Macrocyclization strategy in kinase drug discovery
6. Cobalt catalyzed C-H functionalization for the synthesis of chiral heterocyclic molecules
7. Advancing Proteolysis Targeting Chimeras towards Clinical Drug Developments
8. A future battle, small molecule drugs for cancer stem cell targeted therapy
9. Stem cell therapies for combating emerging and re-emerging viral infections
10. Targeting Autophagy with Pharmacological Small-Molecules to Treat Human Diseases
11. Interferons in human papillomavirus infection: antiviral effectors or immunopathogenic role?
12. Selenium and small molecules: a symbiotic partnership
13. Novel Combinations of CD33-Targeted Immunotherapies
14. Novel payloads of antibody–drug conjugates
15. Antibody-Drug Conjugates (ADCs): A New Generation of Cancer Vaccines
16. mRNA Vaccines: The Next Frontier in Disease Prevention
17. Unravelling the drying techniques of protein biopharmaceuticals
Section 2: Drug discovery case studies
18. Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatmet of multidrig-resistant HIV infections
19. Nirmatrelvir, SIM0417, and RAY1216: Potent and Selective SARS-CoV-2 Main Protease Inhibitors for the Potential Treatment of COVID-19
20. ARV-110: An Androgen Receptor Degrader in the Treatment of Metastatic Castration-Resistant Prostate Cancer
21. Darolutamide: An Androgen Receptor Antagonist for the Treatment of Prostate Cancer
22. Palbociclib, Ribociclib, and Abemaciclib: Potent and Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer
23. Zanubrutinib: A breakthrough in cancer therapy targeting BTK, originating from China and benefiting the global community
24. Discovery of FT-2102 (olutasidenib), an inhibitor of mutant isocitrate dehydrogenase 1, for treatment of relapsed or refractory acute myeloid leukemia
25. Ziftomenib (KO-539): A Potent and Selective Menin Inhibitor for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
26. Pulrodemstat (CC-90011): A Potent, Selective, and Reversible LSD1 Inhibitor
27. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
28. Verquvo, a First-in-Class Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Heart Failure
29. Tafamidis: a Transthyretin Stabilizer for Rare Cardiac Amyloidosis
30. Oliceridine (TRV-130): A Biased Agonist of the μ Opioid Receptor as a Novel Analgesic
31. Sotyktu (Deucravacitinib): The First TYK2 Inhibitor Approved for the Treatment of Psoriasis
32. Bexagliflozin: A SGLT-2 Inhibitor as Antidiabetic Drug Derived From Phlorizin
33. Antidiabetic Drugs Targeted PPARγ: From Full Agonists to Selective Modulators
34. Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis
35. Lecanemab (Leqembi): An Amyloid Beta Monoclonal Antibody Approved for the Treatment of Alzheimer's Disease
- No. of pages: 692
- Language: English
- Edition: 1
- Published: October 1, 2024
- Imprint: Elsevier
- Paperback ISBN: 9780443239328
BY
Bin Yu
Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10.
Affiliations and expertise
School of Pharmaceutical Sciences, Zhengzhou University, ChinaPZ
Peng Zhan
Peng Zhan obtained his B.S. degree from Shandong University, China, in 2005. He then earned his M.S. and Ph.D. degrees in medicinal chemistry from Shandong University in 2008 and 2010. He subsequently joined Shandong University as a Lecturer (2010−2012). From 2012 to 2014, he worked as a postdoctoral fellow funded by Japan Society for the Promotion of Science. He is currently a full professor in the Department of Medicinal Chemistry, Shandong University. His research interests involve the discovery of novel anti-viral (HIV, HBV, influenza, coronavirus, etc.), anti-gout, and anti-cancer agents based on rational drug design and combinatorial chemistry approaches. He also co-edited six books published by People's Medical Publishing House and Springer Nature, respectively and granted 50 patents (30 of them licensed). He currently serves as advisory editorial board member of Journal of Medicinal Chemistry.
Affiliations and expertise
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Shandong University, China